MedTrace Logo

The Influence of Ezetimibe on Gallbladder Function

NCT00634140 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-03-30

No results posted yet for this study

Summary

Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol.

The primary aim of this study is to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis.

Conditions

  • Chronic Acalculous Cholecystitis

Interventions

DRUG

ezetimibe

ezetimibe 10 mg daily for 4 to 6 weeks

DRUG

Placebo

placebo for 4-6 weeks

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Henry A. Pitt, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00634140 on ClinicalTrials.gov